Objectives: Small cell transformation is a well-recognized mechanism of resistance to EGFR-TKI therapy in EGFR-mutant NSCLC, yet it remains a poorly-described phenomenon in ALK-rearranged NSCLC. Conclusions: Given the inevitable development of resistance in ALK + NSCLC, if feasible, re-biopsy on progression should be standard over liquid biopsy. Neuroendocrine carcinoma transformation remains an important mechanism of acquired resistance to lorlatinib. READ ARTICLE
Lung Cancer: 10.1016/j.lungcan.2019.05.025
Authors: Niamh Coleman, Andrew Wotherspoon, Nadia Yousaf, Sanjay Popat
Read More